semaglutide cardiovascular outcomes 2025 news of and tirzepatide for patients with type 2 diabetes in clinical practice Wegovy confers reductions in cardiovascular

When total weight loss is 21%, even 26% of that coming from lean mass represents meaningful absolute numbers

[11] With respect to muscle mass , a concern shared across the class of GLP-1-based weight loss therapies is the potential for loss of lean muscle tissue alongside fat mass during significant caloric restriction

Reference Module in Biomedical Sciences

Nadia Ahmad from Eli Lilly expressed excitement over retatrutide's unique mechanism of action, predicting its transformative impact on the obesity treatment landscape

Drug companies retain large, well-funded legal teams whose sole purpose is to minimize or defeat injury claims

Bret Scher to cut through brain superfood hype and lay out a science-first framework for eating to improve mood, reduce anxiety, and protect memory